Hainan Poly Pharm. Co., Ltd (SHE:300630)

Market Cap	1.39B
Revenue (ttm)	1.31B
Net Income (ttm)	-106.04M
Shares Out	558.01M
EPS (ttm)	-0.24
PE Ratio	n/a
Forward PE	1.98
Dividend	n/a
Ex-Dividend Date	n/a

Volume	44,253,927
Average Volume	25,884,403
Open	2.520
Previous Close	2.490
Day's Range	2.450 - 2.580
52-Week Range	2.050 - 15.270
Beta	0.29
RSI	42.62
Earnings Date	Apr 21, 2025

About Hainan Poly Pharm.

Hainan Poly Pharm. Co., Ltd. engages in research, development, production, and sale of pharmaceutical drugs in China and internationally. The company’s dosage formulations comprise of tablets, capsules, granules, ointments, eye drops, pre-infusion, injection, lyophilization, and oral solutions. It also offers pharmaceutical preparations, active pharmaceutical ingredients, other raw materials, excipients, prescription drugs, and contract manufacturing and contract development and manufacturing services. Hainan Poly Pharm. Co., Ltd. was founded i...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1992
• Employees: 1,565
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 300630

Financial Performance

In 2023, Hainan Poly Pharm.'s revenue was 1.30 billion, a decrease of -19.43% compared to the previous year's 1.62 billion. Earnings were 85.92 million, a decrease of -70.87%.